Literature DB >> 11012622

Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and beta2-microglobulin, respectively.

S D Lawn1, D Rudolph, S Wiktor, D Coulibaly, A Ackah, R B Lal.   

Abstract

The aim of this study was to identify immune markers that are independently associated with HIV infection or TB in vivo. Using commercially available assays, we measured concentrations of five immune markers in sera from 175 out-patients attending medical clinics in Cote D'Ivoire and Ghana, West Africa. Patients were categorized into groups with TB only (TB+HIV-, n = 55), TB and HIV co-infection (TB+HIV+, n = 50), HIV infection only (TB-HIV+, n = 35), or neither infection (TB-HIV-, n = 35). TB+HIV+ and TB-HIV+ groups were matched for blood CD4+ lymphocyte count. Mean +/- s.d. concentrations of beta2-microglobulin were similarly increased in both the TB-HIV+ (5.3+/-2.1 microg/ml, P<0.0001) and the TB+HIV+ (5.0+/-1.5 microg/ml, P<0.0001) groups compared with the TB-HIV- group (2.2+/-1.8 microg/ml), but were only slightly increased in the TB+HIV- group (3.2+/-1.8 microg/ml, P = 0.01). In contrast, mean serum concentrations of soluble tumour necrosis factor receptor type I (sTNF-RI) were similarly elevated in the TB+HIV- (1873+/-799 pg/ml, P<0.0001) and TB+HIV+ (1797+/-571 pg/ml, P<0.0001) groups compared with uninfected subjects (906+/-613 pg/ml), but there was only a small increase in sTNF-RI in the TB-HIV+ group (1231+/-165 pg/ml, P = 0.03). Both TB and HIV infection were associated with substantial elevation of serum concentrations of soluble CD8, soluble CD54, and sTNF-R type II. Analysis of additional samples from groups of TB+HIV- and TB+HIV+ patients receiving anti-TB treatment showed significant and equal reductions in mean serum sTNF-RI concentrations, but no significant change in mean beta2-microglobulin. Thus, serum beta2-microglobulin and sTNF-RI serve as relatively independent markers of HIV infection and TB, respectively, in studies of co-infected persons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012622      PMCID: PMC1905745          DOI: 10.1046/j.1365-2249.2000.01341.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

1.  Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection.

Authors:  S D Lawn; B D Roberts; G E Griffin; T M Folks; S T Butera
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration.

Authors:  I F Hoffman; C S Jere; T E Taylor; P Munthali; J R Dyer; J J Wirima; S J Rogerson; N Kumwenda; J J Eron; S A Fiscus; H Chakraborty; T E Taha; M S Cohen; M E Molyneux
Journal:  AIDS       Date:  1999-03-11       Impact factor: 4.177

3.  Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans.

Authors:  S D Lawn; R J Shattock; J W Acheampong; R B Lal; T M Folks; G E Griffin; S T Butera
Journal:  AIDS       Date:  1999-11-12       Impact factor: 4.177

4.  Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti-tuberculosis treatment.

Authors:  S D Lawn; M O Labeta; M Arias; J W Acheampong; G E Griffin
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

5.  Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation.

Authors:  D Goletti; D Weissman; R W Jackson; N M Graham; D Vlahov; R S Klein; S S Munsiff; L Ortona; R Cauda; A S Fauci
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

6.  Clinical features and serum beta 2-microglobulin levels in HIV-1 positive and negative Tanzanian patients with tuberculosis.

Authors:  N Kennedy; F M Whitelaw; J Gutmann; L Berger; L Uiso; F I Ngowi; S H Gillespie
Journal:  Int J STD AIDS       Date:  1995 Jul-Aug       Impact factor: 1.359

7.  Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection.

Authors:  G Vanham; K Edmonds; L Qing; D Hom; Z Toossi; B Jones; C L Daley; B Huebner; L Kestens; P Gigase; J J Ellner
Journal:  Clin Exp Immunol       Date:  1996-01       Impact factor: 4.330

8.  Predictive markers of survival in HIV-seropositive and HIV-seronegative Tanzanian patients with extrapulmonary tuberculosis.

Authors:  C Richter; M J Koelemay; A B Swai; R Perenboom; D H Mwakyusa; J Oosting
Journal:  Tuber Lung Dis       Date:  1995-12

Review 9.  Immune activation is a dominant factor in the pathogenesis of African AIDS.

Authors:  Z Bentwich; A Kalinkovich; Z Weisman
Journal:  Immunol Today       Date:  1995-04

10.  Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.

Authors:  A R Moss; P Bacchetti; D Osmond; W Krampf; R E Chaisson; D Stites; J Wilber; J P Allain; J Carlson
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-12
View more
  6 in total

1.  Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection.

Authors:  S D Lawn; S T Butera
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects.

Authors:  Harriet Mayanja Kizza; Benigno Rodriguez; Miguel Quinones-Mateu; Muneer Mirza; Htin Aung; Belinda Yen-Lieberman; Colleen Starkey; Libby Horter; Pierre Peters; Joy Baseke; John L Johnson; Zahra Toossi
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

3.  Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy.

Authors:  S Brahmbhatt; G F Black; N M Carroll; N Beyers; F Salker; M Kidd; P T Lukey; K Duncan; P van Helden; G Walzl
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

4.  Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.

Authors:  A Jayakumar; E Vittinghoff; M R Segal; W R MacKenzie; J L Johnson; P Gitta; J Saukkonen; J Anderson; M Weiner; M Engle; C Yoon; M Kato-Maeda; P Nahid
Journal:  Tuberculosis (Edinb)       Date:  2015-05-09       Impact factor: 3.131

Review 5.  Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.

Authors:  S D Lawn; S T Butera; T M Folks
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  C-reactive protein, Neopterin and Beta2 microglobulin levels pre and post TB treatment in The Gambia.

Authors:  Joseph Mendy; Toyin Togun; Olumuyiwa Owolabi; Simon Donkor; Martin O C Ota; Jayne S Sutherland
Journal:  BMC Infect Dis       Date:  2016-03-08       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.